{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:29:03Z","timestamp":1782962943463,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61976223"],"award-info":[{"award-number":["61976223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartandlung.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.hrtlng.2023.11.006","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:43:17Z","timestamp":1700631797000},"page":"36-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Rui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-0877","authenticated-orcid":false,"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2023.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary arterial hypertension: diagnosis, treatment, and novel advances","volume":"203","author":"Maron","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-med-041717-085955","article-title":"New and emerging therapies for pulmonary arterial hypertension","volume":"70","author":"Spiekerkoetter","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0003","first-page":"31","article-title":"Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis","author":"Pitre","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0004","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1164\/rccm.201911-2137OC","article-title":"Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling","volume":"201","author":"He","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018798183","article-title":"Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials","volume":"8","author":"Zheng","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40256-018-00324-2","article-title":"The efficacy and safety of aerosolized iloprost in pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"19","author":"Kuang","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0007","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0008","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0009","first-page":"5","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0010","unstructured":"Deeks J.J., Higgins J., Altman D.G., Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011). The cochrane collaboration; 2011;2:5."},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/oxfordjournals.aje.a009981","article-title":"Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis","volume":"150","author":"Takkouche","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0012","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0013","first-page":"30","article-title":"Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis","author":"Bashashati","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0014","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0016","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0017","unstructured":"Frost A., McLaughlin V., Oudiz R., Tapson V., Murali S., McQueen C., et\u00a0al."},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0018","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0019","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.21987","article-title":"Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study","volume":"35","author":"Sun","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0020","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.amjcard.2013.08.003","article-title":"Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study)","volume":"112","author":"Cha","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0021","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1253\/circj.CJ-16-0097","article-title":"Efficacy and safety of inhaled iloprost in japanese patients with pulmonary arterial hypertension - insights from the IBUKI and AIR studies","volume":"80","author":"Saji","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0022","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jjcc.2016.07.002","article-title":"Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome","volume":"69","author":"Chon","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0023","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0024","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0025","unstructured":"McLaughlin V.V., Oudiz R., Frost A., Tapson V., Murali S., Channick R., et\u00a0al. A randomized, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertension (pah).18."},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0026","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.siny.2015.03.001","article-title":"Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment","volume":"20","author":"Jain","year":"2015","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004757","article-title":"Is anticoagulation beneficial in pulmonary arterial hypertension?","volume":"11","author":"Khan","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0028","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/jpp\/rgab068","article-title":"Osthole improves pulmonary artery hypertension by inducing apoptosis in pulmonary artery smooth muscle cells","volume":"73","author":"Zhu","year":"2021","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020981350","article-title":"Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension","volume":"11","author":"Fernandes","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0030","article-title":"Prostacyclin for pulmonary hypertension in adults","volume":"2005","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0031","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2023.11.006_bib0032","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956323002716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956323002716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T23:20:09Z","timestamp":1720999209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956323002716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"alternative-id":["S0147956323002716"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2023.11.006","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2023.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}